We are live on ! Find out more
PCYC

PHARMACYCLICS INC
PCYC

Delisted

PCYC was delisted on the 22nd of May, 2015.

280 hedge funds and large institutions have $5.29B invested in PHARMACYCLICS INC in 2014 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 103 increasing their positions, 83 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 35

24% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 83

11% more funds holding

Funds holding: 253280 (+27)

2% more capital invested

Capital invested by funds: $5.19B → $5.29B (+$101M)

25% less funds holding in top 10

Funds holding in top 10: 129 (-3)

34% less call options, than puts

Call options by funds: $141M | Put options by funds: $213M

Holders
280
Holders Change
+27
Holders Change %
+10.67%
% of All Funds
8.09%
Holding in Top 10
9
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-25%
% of All Funds
0.26%
New
66
Increased
103
Reduced
83
Closed
35
Calls
$141M
Puts
$213M
Net Calls
-$72.1M
Net Calls Change
-$103M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$876M +$2.43M +18,670 +0.2%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$672M -$123M -942,949 -12%
Ameriprise
3
Ameriprise
Minnesota
$346M +$365M +2,808,154 +439%
Vanguard Group
4
Vanguard Group
Pennsylvania
$341M +$20.6M +158,228 +5%
Fidelity Investments
5
Fidelity Investments
Massachusetts
$248M -$49M -377,195 -13%
Primecap Management
6
Primecap Management
California
$239M
BIT
7
BlackRock Institutional Trust
California
$164M -$13.4M -103,460 -6%
FAM
8
Fred Alger Management
New York
$147M +$51.2M +393,561 +37%
Capital World Investors
9
Capital World Investors
California
$142M -$70.7M -544,023 -28%
Goldman Sachs
10
Goldman Sachs
New York
$131M +$44.3M +340,676 +35%
State Street
11
State Street
Massachusetts
$120M +$4.41M +33,926 +3%
CCI
12
Columbus Circle Investors
$88.6M -$62.2M -478,198 -35%
JHIU
13
Janus Henderson Investors US
Colorado
$82.8M +$23.8M +182,998 +28%
1832 Asset Management
14
1832 Asset Management
Ontario, Canada
$67.2M +$95.5M +734,818 New
BB
15
BB Biotech
Switzerland
$63.8M
Norges Bank
16
Norges Bank
Norway
$59.3M
First Trust Advisors
17
First Trust Advisors
Illinois
$57.2M +$14.2M +109,310 +24%
CCM
18
Cornerstone Capital Management
Minnesota
$51.6M +$66.9M +514,635 New
Morgan Stanley
19
Morgan Stanley
New York
$49M +$28.5M +219,338 +81%
BFA
20
BlackRock Fund Advisors
California
$48M +$4.28M +32,922 +7%
Northern Trust
21
Northern Trust
Illinois
$45.9M +$225K +1,732 +0.4%
TCIM
22
TIAA CREF Investment Management
New York
$45.4M +$19M +146,247 +48%
Susquehanna International Group
23
Susquehanna International Group
Pennsylvania
$41.9M +$9.45M +72,664 +21%
MAA
24
Managed Account Advisors
New Jersey
$41.2M +$47M +361,875 +732%
Franklin Resources
25
Franklin Resources
California
$40M +$21.6M +165,900 +71%

PCYC Hedge Fund Activity: Q1 2014 in Review

280 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in PHARMACYCLICS INC (PCYC) for Q1 2014, worth a combined $5.29B — up 1.9% from $5.19B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new PCYC positions and 35 closed out — a net gain of 31 holders — while 103 added to existing stakes and 83 trimmed.

The largest buyer was Ameriprise, adding an estimated $365M. The largest seller was T. Rowe Price Associates, cutting an estimated $123M.

  • 280 institutional investors held PHARMACYCLICS INC (PCYC) as of Q1 2014, up from 253 in Q4 2013.
  • Funds reported $5.29B of PHARMACYCLICS INC stock for Q1 2014, up 1.9% quarter-over-quarter.
  • 66 funds opened new PHARMACYCLICS INC positions in Q1 2014 and 35 closed out, a net change of +31 holders.
  • The largest PHARMACYCLICS INC buyer in Q1 2014 was Ameriprise, an estimated $365M added.
  • The largest PHARMACYCLICS INC seller in Q1 2014 was T. Rowe Price Associates, an estimated $123M sold.

Based on aggregated 13F filings for Q1 2014.